Stay updated with breaking news from Acticor Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acticor Biotech posted a technical rebound on the Paris Bourse on Friday, after plummeting the previous day due to the failure of its Phase 2/3 trial in stroke treatment.As mid-day approached, the...
Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.The biopharmaceutical...
Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab Key results from this study will be presented at ESOC on May 15,...
University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce...
French biopharmaceutical company Acticor Biotech found itself in the spotlight last week following the successful completion of a clinical trial for the emergency treatment of stroke. Gilles Avenard,...